Obese Patients With Untreated Dyslipidemias (RIO-Lipids)

Sanofi

Status and phase: Completed; Phase 3

Conditions: Obesity; Dyslipidemia

Treatments: Drug: Rimonabant (SR141716)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00029835

EFC4735

Details and patient eligibility

About

To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with untreated dyslipidemia

Enrollment: 1,033 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• BMI must be greater than 27 and less than 40
• Patients with untreated dyslipidemia
• Stable weight (variation of less than 5 kg within 3 months prior to screening visit)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind